girentuximab

girentuximab

A chimeric IgG1 monoclonal antibody that targets carbonic anhydrase IX. Phase-1 and -2 studies of girentuximab plus low-dose IFN-alpha in patients with progressive metastatic renal cell carcinoma indicated that the combination therapy was safe, well tolerated and demonstrated clinical benefit in the patient population.